Zobrazeno 1 - 7
of 7
pro vyhledávání: '"B. E. Brockstein"'
Autor:
E. B. Lamont, D. Hayreh, K. E. Pickett, J. J. Dignam, M. A. List, K. M. Stenson, D. J. Haraf, B. E. Brockstein, S. A. Sellergren, E. E. Vokes
Publikováno v:
JNCI Journal of the National Cancer Institute. 95:1370-1375
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64d482807652065643cf451cf76e1dfe
https://doi.org/10.1093/jnci/djg035
https://doi.org/10.1093/jnci/djg035
Publikováno v:
Seminars in radiation oncology. 9(2 Suppl 1)
A series of phase I and phase II studies investigating multiagent concomitant chemoradiotherapy in patients with poor-prognosis head and neck cancer have been conducted at the University of Chicago. Drug combinations initially included 5-fluorouracil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c331beb60a35965c049761985760520e
https://pubmed.ncbi.nlm.nih.gov/10210543
https://pubmed.ncbi.nlm.nih.gov/10210543
Publikováno v:
Oncologic Therapies ISBN: 9783540781080
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ed3a429289fd505e015b1ec9754032b
https://doi.org/10.1007/978-3-642-97988-0_40
https://doi.org/10.1007/978-3-642-97988-0_40
Autor:
T. D. Peabody, B. E. Brockstein
Publikováno v:
Oncologic Therapies ISBN: 9783540781080
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc5a782dfae35b052568737429e05676
https://doi.org/10.1007/978-3-642-97988-0_41
https://doi.org/10.1007/978-3-642-97988-0_41
Publikováno v:
Oncology (Williston Park, N.Y.). 12(10 Suppl 7)
The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (5% of patients). Patients with stage I-II disease are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab02611a4357a2578222c7575a1cc866
https://pubmed.ncbi.nlm.nih.gov/9830623
https://pubmed.ncbi.nlm.nih.gov/9830623
Autor:
N J, Vogelzang, S, Mani, R L, Schilsky, R H, Ansari, D, Taber, S N, Rhinehart, J C, Garcia, S C, Meyer, R, Mick, B E, Brockstein, W M, Stadler, M J, Ratain, E E, Vokes
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(4)
Pyrazine diazohydroxide (PZDH) is a novel antitumor agent that forms DNA adducts via the reactive pyrazine diazonium ion. In a recent Phase I study of PZDH, we identified a recommended Phase II dose of 100 mg/m2/day x 5, given as a 5-min i.v. bolus w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cf9b3688017cf2fef9e8a0efb2fac771
https://pubmed.ncbi.nlm.nih.gov/9563886
https://pubmed.ncbi.nlm.nih.gov/9563886
Autor:
J. K. Salama, K. M. Stenson, E. O. Kistner, B. B. Mittal, A. Argiris, M. E. Witt, F. Rosen, B. E. Brockstein, E. E. W. Cohen, D. J. Haraf, E. E. Vokes
Publikováno v:
Annals of Oncology. Oct2008, Vol. 19 Issue 10, p1787-1787. 1p.